anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To solve the following conventional problem: prescription history information of a patient receiving medical examinations in a plurality of medical institutions is not smoothly provided to a medical institution.  <P>SOLUTION: A pharmacy side computer 12 has a two-dimensional code production means 16. The two-dimensional code production means 16 produces two-dimensional code information having contents related to a medicine of the patient inputted by an input means 13, and outputs the contents related to the inputted medicine and the two-dimensional code information produced by the two-dimensional code production means to an output means 14. The output means 14 prints the contents related to the medicine by characters and a two-dimensional code 22b by the two-dimensional code information on paper to prepare a medicine description with two-dimensional code 22. A two-dimensional code reading means 5 of a medical treatment side computer 2 reads the two-dimensional code 22b printed on the medicine description with two-dimensional code 22. A two-dimensional code decoding means 7 decodes the two-dimensional code 22b, converts it to character information, and stores it in a storage means 8.  <P>COPYRIGHT: (C)2007,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a method for promoting antioxidative activity of galloyl catechins.  <P>SOLUTION: A fragment relating to binding with EGCG (epigallocatechin gallate) is specified in 67kDa laminin receptor (67LR). A peptide and its modified peptide having binding activity with catechins, especially galloyl catechins, are provided. A peptide with antioxidative activity derived from 67LR protein is provided. Furthermore, not only the peptide derived from 67LR protein a new use of a basic amino acid, that is, the promotive method of antioxidative activity of galloyl catechins characterized by using a food or a medicinal composition containing galloyl catechins and the basic amino acid is provided. Also a promotive agent of antioxidative activity of galloyl catechins containing the basic amino acid is provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention discloses a method for separating syringin from ilex rotunda. The medicinal herb is crushed into fine powder and is reflowed and extracted through benzene. The extracted gruff is dried in air and is reflowed and extracted through acetone. Filtrates are mixed and extracting solution is condensed and stands for the isolation of white powder, and the extracted gruff is filtrated after the isolation is completed. Educt is washed by acetone and undergoes repeated recrystallization with mixed acetone-methanol solution, and finally methanol is used again for recrystallization to obtain the white raphide of syringin. In the first place, the method adopts ilex rotunda as the raw material with low cost and abundant resource. The average content of syringin in ilex rotunda is determined as 2.55 percent through an HPLC method. Thus, abundant raw material for preparing syringin and derivates thereof can be provided. In the next place, through the method, a plurality of experiments on the dry bark of holly ilex rotunda are carried out to obtain the syringin with high purity; in addition, the method which saves time and labor with good stability is an effective and simple method for extraction and separation.
The emergence of novel H1N1 influenza in 2009 has a great impact to the societies in Taiwan and worldwide. The patients of pediatric haemato-oncology have a higher risk for novel H1N1 influenza infection than general population, and they are strongly recommended to receive novel H1N1 vaccination. However, there is no previous data to answer how the efficacy and effectiveness of novel H1N1 vaccination is in patients of pediatric haemato-oncology. This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in these patients. Thus two blood samples will be drawn. The first sample will be collected before the vaccination and the second one will be collected three weeks after the vaccination (If the patient is younger than 9 years old, the third sample will be collected three weeks after the booster vaccination). Titer of H1N1 influenza virus antibodies will be determined by hemagglutinin inhibition assay (HAI). A HAI titer with a 4-fold rise or greater is defined as seroconversion. Study subjects with seroconversion are regarded as responsiveness to the vaccination. We will analyze seroconversion rate as well. Meanwhile, if the patient presents influenza-like symptoms, we will perform throat swab or nasal swab for influenza rapid test, viral isolation, and novel H1N1 influenza PCR to confirm the diagnosis. After the study, we will be able to know whether or not current novel H1N1 influenza vaccination schedule is adequate and efficient for pediatric haemato-oncology patients.
PROBLEM TO BE SOLVED: To identify an animal infected with Pseudo Rabies Virus(PRV) by subjecting a morbid animal to vaccination of PRV lacking glycoprotein gI or gp63. SOLUTION: pPR28 is consumed by PVuII and a cut piece, containing E.coli replication start point and bla gene, is recirculated to produce a plasmid comprising 4.9kbPvuII/BamH17 PVR fragment containing DNA arrangement for gI thus obtaining plasmid pPR28-1. BamH17 is subjected to subcloning, consumed, labeled and arranged. DNA arrangements for glycoprotein gp63 and gI are presented on arrangement tables (arrangement number 2 and 3). An animal infected actively with PRV can be detected using this DNA. Presence of PRV can be detected by wiping nose or throat using a cotton swab for the purpose of sampling and subjecting the sample to a standard hybridization of DNA/DNA.
Participants will receive 8 weeks of CBT4CBT and incentives for timely shipping. In addition, those in the CM Condition will receive at least $20 for each PEth-negative sample. Participants will receive an additional $5 for each week of consecutive negative PEth tests, with a $90 cap. In Initiation Phase, participants will attend virtual visits, provide PEth samples, and be rewarded for a decrease in PEth weekly. Maintenance Phase will begin when a participant's PEth sample is \< 20 ng/mL. In Maintenance Phase, participants will attend visits and submit PEth samples every two weeks for four weeks (i.e., weeks 6 \& 8). They will then attend visits and submit PEth samples every four weeks (weeks 12, 16, 20, 24), and on week 26. If participants submit a positive PEth sample, they will return to Initiation Phase and receive $20 for their next negative sample. Participants will attend visits and submit samples weekly until their PEth level is \< 20 ng/mL and they restart Maintenance Phase.
This disclosure provides compounds having Bcl inhibitory activity. Aminophosphonate compounds typically comprise a P-phenyl aminophosphonate moiety substituted with an N-aryl or N-heteroaryl group. The P-phenylaminophosphonate module can be optionally substituted at phosphorus with sulfur (=s) instead of oxygen (=o), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus may be a cyclic linkage to an N-substituted nitrogen atom attached to phosphorus to provide a heterocyclic ring. By introducing such a ring constraint between two phosphorus substituents of the core linking module, an advantageous binding conformation can be promoted in the compound. The selected compounds promote apoptosis in senescent cells and may be developed for use in the treatment of senescence-associated conditions, such as osteoarthritis, ocular diseases, pulmonary diseases, and atherosclerosis. The selected compounds promote apoptosis in cancer cells and may be developed as chemotherapeutic agents.
Although the past 40 years has witnessed a substantial improvement in the acute and chronic management of persons with SCI, mortality remains high during the first year post-injury, and pulmonary complications including pneumonia, lung collapse (atelectasis), respiratory failure, and thromboembolism are the predominant cause. The propensity for pulmonary complications among subjects with SCI stems from paralysis of respiratory muscles. Injury to the cervical and upper thoracic cord significantly compromises function of the diaphragm, intercostal muscles, accessory respiratory muscles, and abdominal muscles. Respiratory muscle dysfunction is manifest as diminution in lung volumes, reduction in maximal static inspiratory and expiratory mouth pressures (MIP and MEP, respectively), and reduction in peak cough pressure and flow. Cough effectiveness is contingent upon both inspiratory and expiratory muscle strength; increasing the pressure-generating capacity of the inspiratory and expiratory muscles in persons with tetraplegia and high paraplegia may, therefore, translate to improved cough effectiveness and reduction in the propensity for atelectasis and, possibly, pneumonia.

Respiratory muscle training, often utilizing simple hand-held portable resistive or threshold training devices, appears to have marginal effects on vital capacity and maximal static mouth inspiratory and expiratory pressures (MIP and MEP, respectively), although data is inconclusive. Pharmacologic interventions to improve respiratory muscle strength have received little attention in the SCI population. Studies involving oral beta-2 adrenergic agonists, which have been shown to elicit anabolic effects on skeletal muscle in young men and an increase in muscle strength among patients with facioscapulohumeral muscular dystrophy, have also demonstrated salutary effects in persons with SCI. There are many foreseeable advantages of a pharmacologic approach to improve respiratory muscle strength in persons with SCI. For instance, RMT can be physically demanding and time consuming, compliance can be an issue, and sustainable improvements have not been realized. The intent in the present proposal is to enroll a targeted cohort of 24 comparatively weaker subjects with tetraplegia and high paraplegia in a randomized, double-blind, placebo-controlled, parallel group trial to assess the effects of an oral beta-2 agonist upon respiratory muscle strength and cough effectiveness.
A system, apparatus and method manages a product inventory of two or more vendors. A demand for each product at each vendor is determined based on a product utilization data stored in one or more databases. One or more product transfers are generated based on the demand for each product at each vendor and a product inventory data stored in the one or more databases. The one or more product transfers are bundled together by vendor-to-vendor pairings. Each transfer bundle is provided to the vendors identified in the transfer bundles. An approval, a modification or a denial is received for each transfer bundle from the vendors identified in the transfer bundles. One or more transfer orders are created for the transfer bundles that are approved and modified.
The invention relates to a Chinese olive mixture for stopping cough and a preparing method thereof. The preparing method comprises using ethanol water to serve as solvent for fritillaria cirrhosa, dipping and filtering to obtain extracting solution; decocting twelve raw material medicines of honey roasted flos farfarae, shell-removed ginkgo, rhizoma pinelliae preparata, liquorice honey roasted fructus aristolochiae, gypsum, bitter apricot seed (fried), lily, scutellaria baicalensis, honey roasted ephedra, honey roasted white mulberry root-bark and Chinese olive; and mixing and concentrating the extracting solution and decoction and removing deposit, and obtaining the Chinese olive mixture by adding dried honey. The Chinese olive mixture mainly treats the symptoms of cold and external infection, phlegmy heat or phlegm and infected by cold, block of lung-qi, internal obstruction, heat transmission, cough, much phlegm and shortness of breath. The Chinese olive mixture is fast in effect taking, stable in quality, convenient to carry and easy to store. The preparing method adopts a filtering method to extract effective ingredients of the fritillaria cirrhosa and adopts a water extraction method to extract effective ingredients of the other medicines so as to reduce operation and improve extraction efficiency. The deposit effect is the best when filtering solution is merged and concentrated to a relative density of 1.05-1.09 (measured at 80 DEG C), deposit removing is facilitated, and product quality is ensured to be stable.
Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION.) 

An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION.) 

An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years. 

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
Auto-vaccines are prepared by growing micro-organisms taken from the patient on a medium containing a concentrated solution obtained from vegetable substances rich in sugar and containing fructose, and a vegetable thickening agent, such as agar-agar, at a temperature corresponding to the body temperature of the patient.  The culture period varies from 2-20 hours.  The culture medium used is preferably that containing expressed banana juice, described in Specification 313,514, [Class 81 (i), Disinfecting &c.].  The micro-organisms may be obtained, according to the particular disease, from the faeces, sputum, tonsils, vagina or other part of the body.  In cases where the germ relationships normal to the particular disease are disturbed the part from which the micro-organisms are to be taken may be re-stocked with the missing organisms by treatment with a culture thereof which has been weakened, but not killed, by heat treatment, before the germs for the preparation of the vaccine are taken.  Fecal germs are obtained from a filtered physiological sodium chloride solution of faeces and are grown on a banana-agar plate and the germs so obtained are then grown on banana-agar plates and a similar plate containing also sterile human blood.  The cultures are then separately killed and mixed for use in a vaccine.  In gonorrhaea, pus from the urethra is first inoculated on a plate containing also white of egg and the vaccine is prepared by cultivating the germs so obtained on plates free from white of egg.  In certain forms of tuberculosis, empyema, and asthma a vaccine from fecal germs is first injected to produce expectoration and a vaccine is then prepared from the sputum.  A mixed vaccine is also used which contains both sputum germs and fecal germs.  The Specification contains instructions for preparing vaccines for treating a large number of specified diseases.
The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably said virus capsid is an adenovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably joint related diseases.
Collaborative Care Model (CoCM) includes a care manager, a defined population of patents/registry for tracking inclusion and progress, validated patient-reported outcome measures, and weekly inter-professional team meetings. This arm includes the use of an inter professional team to triage, plan and deliver care. the PRISM intervention, a brief, skills-based program targeting 4 resilience resources, will be delivered 1:1 as part of this treatment arm.
In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
The invention relates to the field of the quality control on traditional Chinese medicine, specifically to a quality control method for erigeron breviscapus(Vant.) hand-mazz. The method comprises a fingerprint detection method and a multiple-indicative content detection method for erigeron breviscapus (Vant.) hand-mazz, wherein the fingerprint detection method employs UPLC detection method, through which 24 characteristic peaks are found and 8 characteristic peaks are ascribed. By using content detection method for erigeron breviscapus(Vant.) hand-mazz., the UPLC-PDA method, contents of following constituents are determined: erigeroside, chlorogenic acid, breviscpini glycoside, Scutellarin, 3,4-0-dicaffeoylquinic acid, 3,5-0-dicaffeoylquinic acid and 4,5-0-dicaffeoylquinic acid. Compared with the prior art, the fingerprint detection method and the multiple-indicative content detection method for erigeron breviscapus (Vant.) hand-mazz are improved in the invention, so that the quality of erigeron breviscapus (Vant.) hand-mazz. can be controlled in a convenient, rapid and accurate manner, thereby ensuring the quality of erigeron breviscapus (Vant.) hand-mazz. stable, uniform and controllable.
FIELD: medicine. SUBSTANCE: invention describes new process for preparing 6α,9α-difluorinated steroids of formula I: 6α,9α wherein R is hydrogen atom or ester residue. The process comprises treating compound of formula II:   with oxidative destructing agent to give compound of formula III:   wherein functional ketone group in position 3 is protected in the form of enol ether or ester, and functional acid group is optionally protected in position   in the form of ester to give compound of formula IV: 17β, wherein R is as defined above, and   is ether or ester enol residue which is treated with electrophilic fluorinating agent to give compound of formula V: R 1 , compound is treated with nucleophilic fluorinating agent to give compound of formula I which is, when R is ester residue, optionally saponified to give corresponding acid. The process is advantageous in that only functional ketone group is protected in position 3 in the form of enol ether or ester to give compound of formula IV. The invention also describes new compounds of formula VI:   wherein R is as defined in formula I, X is hydrogen or fluorine atom, and Y bonded with dotted lines is essentially system of 3-keto  , or X is hydrogen atom, and Y bonded with dotted lines is essentially system of Δ4 in which 3-OR 1  Δ3,5 is as defined in formula I. Compounds are useful as intermediate compounds for preparing steroidal drugs. EFFECT: more efficient preparation process. 10 cl, 4 ex
Pyloromyotomy for pyloric stenosis has traditionally been performed via an open technique. With advancements in minimally invasive surgery in infants a laparoscopic approach has been developed. These two approaches have never been critically evaluated with regard to superiority of one technique over the other. This is a prospective randomized trial involving infants with pyloric stenosis. It will enroll 100 patients in each arm (statistical and power analysis was performed by Steve Simon, PhD). Parental consent will be obtained and the patients will be randomized to undergo open or laparoscopic pyloromyotomy. Patient age at diagnosis, electrolyte disturbances at diagnosis, ultrasound findings, operative approach, length of pyloromyotomy, operative times, time to tolerating full feeds, number of emesis episodes, length of hospitalization, operative charges, and hospital charges will be collected for comparison between the groups.
BACKGROUND: Emergency department (ED) utilization following surgery is poorly understood and places immense strain on the healthcare system, being responsible for up to $38 billion in wasteful spending annually. The aim of this study was to quantify ED utilization following bariatric procedures to identify causes and areas of improvement.
MATERIALS AND METHODS: A retrospective review of a prospectively maintained database was conducted for all patients who underwent metabolic bariatric surgery (MBS) between November 2006 and June 2019. The study includes 4703 patients across 8 hospitals in a single health system. Patients who returned to the ED within 30 and 90 days were analyzed for relation to surgery and preventability.
RESULTS: Of the 4703 patients that underwent MBS, 907 (19.3%) visited the ED at least once within 90 days and 350 (7.4%) required hospital readmission. The most common bariatric procedure performed was the Roux-en-Y Gastric Bypass (RYGB) (3716/4703) with an average BMI of 43.8. The median length between discharge and ED visit was 19 days. Under 50% of patients called prior to ED presentation and 61% of these ED visits resulted in discharge.
CONCLUSION: While hospital readmissions following MBS have been scrutinized in literature, investigation of ED utilization remains scarce. Our study is one of few to investigate postoperative ED utilization up to 90 days following bariatric intervention. A clear opportunity exists to improve discharge education and early post-discharge communication. This would additionally alleviate burden to allow focus on the acutely ill.